Bionano Genomics
BNGO
126 hedge funds and large institutions have $90.6M invested in Bionano Genomics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 26 closing their positions.
114% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $749K
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
0% less ownership
Funds ownership: 0.05% → 0.04% (-0%)
12% less funds holding
Funds holding: 143 → 126 (-17)
48% less capital invested
Capital invested by funds: $176M → $90.6M (-$84.9M)
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$607K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$513K |
| 4 |
ACS
Archford Capital Strategies
Swansea,
Illinois
|
+$455K |
| 5 |
State Street
Boston,
Massachusetts
|
+$394K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.1M |
| 2 |
Millennium Management
New York
|
-$1.71M |
| 3 |
Goldman Sachs
New York
|
-$632K |
| 4 |
Morgan Stanley
New York
|
-$387K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$299K |
BNGO Hedge Fund Activity: Q1 2023 in Review
126 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q1 2023, worth a combined $90.6M — down 48% from $176M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BNGO and 9 opened new positions — a net loss of 17 holders — while 35 trimmed existing stakes and 41 added.
The largest buyer was Nuveen, adding an estimated $1.2M. The largest seller was Citadel Advisors, cutting an estimated $2.1M.
- 126 institutional investors held Bionano Genomics (BNGO) as of Q1 2023, down from 143 in Q4 2022.
- Funds reported $90.6M of Bionano Genomics stock for Q1 2023, down 48% quarter-over-quarter.
- 9 funds opened new Bionano Genomics positions in Q1 2023 and 26 closed out, a net change of -17 holders.
- The largest Bionano Genomics buyer in Q1 2023 was Nuveen, an estimated $1.2M added.
- The largest Bionano Genomics seller in Q1 2023 was Citadel Advisors, an estimated $2.1M sold.
Based on aggregated 13F filings for Q1 2023.